心力衰竭的免疫学与保存的喷射分数
Brandon Wang1, Stanislovas S Jankauskas1, Pasquale Mone1
1Department of Medicine (Division of Cardiology), Wilf Family Cardiovascular Research Institute, Einstein Institute for Neuroimmunology and Inflammation (INI), Albert Einstein College of Medicine, New York, NY, USA.
Expert review of clinical immunology
|November 6, 2025
概括
免疫失调驱动心力衰竭与保存的喷射分数 (HFpEF). 了解这些免疫路径是开发新疗法的关键,为这个不断增长的患者群体开发新疗法.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 翻译医学是一种翻译医学.
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭与慢性炎症和免疫系统功能障碍有关.
- 天生的免疫和适应性免疫都有助于HFpEF病理生理学,包括心肌重塑和内皮功能障碍.
研究的目的:
- 审查免疫路径在HFpEF中的作用.
- 探索潜在的免疫调节疗法和HFpEF相关生物标志物.
主要方法:
- 对HFpEF免疫学贡献的现有证据的系统审查.
- 对实验模型分析,将炎症与HFpEF特征联系起来.
- 免疫调节治疗方法和生物标志物的评估.
主要成果:
- 免疫细胞透 (巨细胞,巨细胞,T细胞) 和促炎细胞因子都与HFpEF有关.
- 在HFpEF模型中,系统性炎症与心肌纤维化,微血管功能障碍和心肌细胞度相关.
- 几种免疫调节策略显示出对HFpEF的治疗前景.
结论:
- 针对炎症为HFpEF提供了潜在的治疗途径.
- 临床试验中的免疫分析可以促进个性化治疗策略.
- 对免疫介导机制的进一步研究对于推进HFpEF治疗至关重要.
相关概念视频
Pathophysiology of Heart Failure
2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Heart Failure II: Pathophysiology
658
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
658
Heart Failure I: Introduction
653
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
653
Heart Failure IV: Classification and Diagnostic Evaluation
281
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
281
Heart Failure III: Clinical Manifestations
430
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
430
Heart Failure VI: Adjunct Therapies
228
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
228


